Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude Neuromodulation draws warning letter

This article was originally published in The Gray Sheet

Executive Summary

FDA warning letter dated July 1 cites non-conformities with current good manufacturing practices at St. Jude's Neuromodulation division facilities in Plano, Tex., and Hackettstown, N.J., which were observed during FDA inspections in March and April. St. Jude says it has already begun addressing the issues, which pertain to manufacturing process and documentation issues, and not specific device deficiencies, according to the company. FDA says it will not approve any St. Jude Neuromodulation PMA application until the warning letter is resolved. But St. Jude notes that it does not have any major neuromodulation device filings pending. The company recently completed enrollment of a pivotal study of its Libra and LibraXP deep brain stimulation systems for symptomatic Parkinson's disease. The company says it expects to file a PMA for the indication in about 18 months

You may also be interested in...



EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.

Topics

UsernamePublicRestriction

Register

PS017586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel